Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Archer, V., Ochi Lohmann, T., Wang, L., Kowanetz, M., Lin, W., Sandler, A., & West, H. (n.d.). lBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095323404.0x000034